60 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat http://www.zacks.com/stock/news/901554/alkermes-alks-q1-earnings-increase-y-y-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-901554 Apr 30, 2020 - Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.
Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling http://www.zacks.com/stock/news/900859/glaxo-gsk-q1-earnings-beat-on-covid-19-related-stockpiling?cid=CS-ZC-FT-analyst_blog|earnings_article-900859 Apr 30, 2020 - Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine http://www.zacks.com/stock/news/899331/healthcare-etfs-to-gain-on-progress-in-coronavirus-vaccine?cid=CS-ZC-FT-etf_news_and_commentary-899331 Apr 29, 2020 - The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Beloved JNJ Shares Are Too Expensive https://seekingalpha.com/article/4340994-beloved-jnj-shares-are-too-expensive?source=feed_sector_healthcare Apr 29, 2020 - Though I love the company, JNJ trading at a 17.4x earnings multiple despite earnings guidance for the year cut 15%. JNJ shares have rebounded sharply of their March lows to the tune of 40%. The Medica
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax http://www.zacks.com/stock/news/897526/the-zacks-analyst-blog-highlights-moderna-johnson-johnson-sanofi-and-novavax?cid=CS-ZC-FT-press_releases-897526 Apr 29, 2020 - The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
3 Stocks to Benefit From Race to Develop Coronavirus Vaccines http://www.zacks.com/stock/news/894002/3-stocks-to-benefit-from-race-to-develop-coronavirus-vaccines?cid=CS-ZC-FT-analyst_blog|investment_ideas-894002 Apr 28, 2020 - Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS http://www.zacks.com/stock/news/891794/big-drug-stock-q1-earnings-due-on-apr-28-mrk-pfe-and-nvs?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-891794 Apr 27, 2020 - Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y http://www.zacks.com/stock/news/891610/bayer-bayry-q1-earnings-beat-estimates-sales-rise-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-891610 Apr 27, 2020 - Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.
Johnson & Johnson and AbbVie Earn a New FDA Approval for Imbruvica https://www.fool.com/investing/2020/04/22/johnson-johnson-and-abbvie-earn-a-new-fda-approval.aspx?source=iedfolrf0000001 Apr 22, 2020 - The cancer drug is now approved for 11 different indications.
The 10 Best Dividend Stocks for 2020 https://www.fool.com/investing/2020/04/22/the-10-best-dividend-stocks-for-2020.aspx?source=iedfolrf0000001 Apr 22, 2020 - If you're in search of yield in the stock market, these outstanding businesses could make for excellent investments.

Pages: 123456

Page 1>